In conclusion, we have demonstrated that the analysis of ESPL1, PTTG1 and PTTG1IP gene expression levels by qRT-PCR in the peripheral blood of patients at the time of ID can contribute to an early individualized TKI therapy in CML. This evidence concerns the gene ESPL1 and chronic myelogenous leukemia, BCR-ABL1 positive.